Combination of Modafinil and d-amphetamine for the Treatment of Cocaine Dependence: A Preliminary Investigation

Joy M Schmitz, Nuvan Rathnayaka, Charles E Green, F Gerard Moeller, Anne E Dougherty, John Grabowski, Joy M Schmitz, Nuvan Rathnayaka, Charles E Green, F Gerard Moeller, Anne E Dougherty, John Grabowski

Abstract

Background: Two stimulant medications, modafinil and d-amphetamine, when tested individually, have shown safety and efficacy for treatment of cocaine addiction. We hypothesized that the combination of modafinil and d-amphetamine, at low doses, would show equivalent or greater benefit in reducing cocaine use compared to higher doses of each individual medication or placebo.

Methods: Sixteen week, randomized, parallel-group design with four treatment arms comparing placebo to modafinil 400 mg; d-amphetamine 60 mg; modafinil 200 mg plus d-amphetamine 30 mg. Primary outcome variables, retention and cocaine use, were analyzed on the sample of 73 participants who received the first dose of the study medication.

Results: Retention rates did not differ between groups and were generally low, with 40% remaining in treatment at week 12 and 20% at week 16. Participants receiving the combination of modafinil and d-amphetamine showed a trend of increased cocaine use over time with a corresponding low Bayesian probability of benefit (33%). Relatively better cocaine outcomes were observed in the placebo and d-amphetamine only groups. The study medications were generally well-tolerated with few adverse effects, yet rates of adherence were suboptimal (≤80%).

Conclusion: Data from this preliminary investigation fail to provide evidential support for conducting a larger study of this dual-agonist medication combination for treatment of cocaine dependence.

Keywords: clinical trial; cocaine dependence; d-amphetamine; modafinil.

Figures

Figure 1
Figure 1
Probability of cocaine use by medication condition and time.

References

    1. Anderson A. L., Reid M. S., Li S. H., Holmes T., Shemanski L., Slee A., Smith E. V., Kahn R., Chiang N., Vocci F., Ciraulo D., Dackis C., Roache J. D., Salloum I. M., Somoza E., Urschel H. C., III, Elkashef A. M. (2009). Modafinil for the treatment of cocaine dependence. Drug Alcohol Depend. 104, 133–13910.1016/j.drugalcdep.2009.04.015
    1. Bayarri M. J., Berger J. O. (2004). The interplay of bayesian and frequentist analysis. Stat. Sci. 19, 58–8010.1214/088342304000000116
    1. Businelle M. S., Rash C. J., Burke R. S., Parker J. D. (2009). Using vouchers to increase continuing care participation in veterans: does magnitude matter? Am. J. Addict. 18, 122–12910.1080/10550490802545125
    1. Carroll K. M., Fenton L. R., Ball S. A., Nich C., Frankforter T. L., Shi J., Rounsaville B. J. (2004). Efficacy of disulfiram and cognitive behavior therapy in cocaine-dependent outpatients: a randomized placebo-controlled trial. Arch. Gen. Psychiatry 61, 264–27210.1001/archpsyc.61.3.264
    1. Dackis C. A., Kampman K. M., Lynch K. G., Pettinati H. M., O’Brien C. P. (2005). A double-blind, placebo-controlled trial of modafinil for cocaine dependence. Neuropsychopharmacology 30, 205–21110.1038/sj.npp.1300701
    1. Del Boca F. K., Kranzler H. R., Brown J., Korner P. F. (1996). Assessment of medication compliance in alcoholics through UV light detection of a riboflavin tracer. Alcohol. Clin. Exp. Res. 20, 1412–141710.1111/j.1530-0277.1996.tb01142.x
    1. Elkashef A., Vocci F. (2003). Biological markers of cocaine addiction: implications for medications development. Addict. Biol. 8, 123–13910.1080/1355621031000117356
    1. Ferraro L., Tanganelli S., O’Connor W. T., Antonelli T., Rambert F., Fuxe K. (1996). The vigilance promoting drug modafinil increases dopamine release in the rat nucleus accumbens via the involvement of a local GABAergic mechanism. Eur. J. Pharmacol. 306, 33–3910.1016/0014-2999(96)00182-3
    1. Grabowski J., Rhoades H., Schmitz J., Stotts A., Daruzska L. A., Creson D., Moeller F. G. (2001). Dextroamphetamine for cocaine-dependence treatment: a double-blind randomized clinical trial. J. Clin. Psychopharmacol. 21, 522–52610.1097/00004714-200110000-00010
    1. Grabowski J., Rhoades H., Stotts A., Cowan K., Kopecky C., Dougherty A., Moeller F. G., Hassan S., Schmitz J. (2004). Agonist-like or antagonist-like treatment for cocaine dependence with methadone for heroin dependence: two double-blind randomized clinical trials. Neuropsychopharmacology 29, 969–98110.1038/sj.npp.1300392
    1. Grabowski J., Roache J. D., Schmitz J. M., Rhoades H., Creson D., Korszun A. (1997). Replacement medication for cocaine dependence: methylphenidate. J. Clin. Psychopharmacol. 17, 485–48810.1097/00004714-199712000-00008
    1. Green C. E., Moeller F. G., Schmitz J. M., Lucke J. F., Lane S. D., Swann A. C., Lasky R. E., Carbonari J. P. (2009). Evaluation of heterogeneity in pharmacotherapy trials for drug dependence: a Bayesian approach. Am. J. Drug Alcohol Abuse 35, 95–10210.1080/00952990802647503
    1. Gurrin L. C., Kurinczuk J. J., Burton P. R. (2000). Bayesian statistics in medical research: an intuitive alternative to conventional data analysis. J. Eval. Clin. Pract. 6, 193–20410.1046/j.1365-2753.2000.00216.x
    1. Herin D. V., Rush C. R., Grabowski J. (2010). Agonist-like pharmacotherapy for stimulant dependence: preclinical, human laboratory, and clinical studies. Ann. N. Y. Acad. Sci. 1187, 76–10010.1111/j.1749-6632.2009.05145.x
    1. Longo M., Wickes W., Smout M., Harrison S., Cahill S., White J. M. (2010). Randomized controlled trial of dexamphetamine maintenance for the treatment of methamphetamine dependence. Addiction 105, 146–15410.1111/j.1360-0443.2009.02717.x
    1. Madras B. K., Xie Z., Lin Z., Jassen A., Panas H., Lynch L., Johnson R., Livni E., Spencer T. J., Bonab A. A., Miller G. M., Fischman A. J. (2006). Modafinil occupies dopamine and norepinephrine transporters in vivo and modulates the transporters and trace amine activity in vitro. J. Pharmacol. Exp. Ther. 319, 561–56910.1124/jpet.106.105312
    1. Margolin A., Kosten T. R., Avants S. K., Wilkins J., Ling W., Beckson M., Arndt I. O., Cornish J., Ascher J. A., Li S. H., Bridge P. (1995). A multicenter trial of bupropion for cocaine dependence in methadone-maintained patients. Drug Alcohol Depend. 40, 125–13110.1016/0376-8716(95)01198-6
    1. McLellan A. T., Kushner H., Metzger D., Peters R., Smith I., Grissom G., Pettinati H., Argeriou M. (1992). The fifth edition of the addiction severity index. J. Subst. Abuse Treat. 9, 199–21310.1016/0740-5472(92)90062-S
    1. Moeller F. G., Schmitz J. M., Herin D., Kjome K. L. (2008). Use of stimulants to treat cocaine and methamphetamine abuse. Curr. Psychiatry Rep. 10, 385–39110.1007/s11920-008-0062-x
    1. Mooney M. E., Herin D. V., Schmitz J. M., Moukaddam N., Green C. E., Grabowski J. (2009). Effects of oral methamphetamine on cocaine use: a randomized, double-blind, placebo-controlled trial. Drug Alcohol Depend. 101, 34–4110.1016/j.drugalcdep.2008.10.016
    1. Petrakis I. L., Carroll K. M., Nich C., Gordon L. T., McCance-Katz E. F., Frankforter T., Rounsaville B. J. (2000). Disulfiram treatment for cocaine dependence in methadone-maintained opioid addicts. Addiction 95, 219–22810.1046/j.1360-0443.2000.9522198.x
    1. Poling J., Oliveto A., Petry N., Sofuoglu M., Gonsai K., Gonzalez G., Martell B., Kosten T. R. (2006). Six-month trial of bupropion with contingency management for cocaine dependence in a methadone-maintained population. Arch. Gen. Psychiatry 63, 219–22810.1001/archpsyc.63.2.219
    1. Rothman R. B., Baumann M. H., Dersch C. M., Romero D. V., Rice K. C., Carroll F. I., Partilla J. S. (2001). Amphetamine-type central nervous system stimulants release norepinephrine more potently than they release dopamine and serotonin. Synapse 39, 32–4110.1002/1098-2396(20010101)39:1<32::AID-SYN5>;2-3
    1. Sayre S. L., Evans M., Hokanson P. S., Schmitz J. M., Stotts A. L., Averill P., Grabowski J. (2004). “Who gets in?” Recruitment and screening processes of outpatient substance abuse trials. Addict. Behav. 29, 389–39810.1016/j.addbeh.2003.08.010
    1. Schmitz J. M., Lindsay J. A., Stotts A. L., Green C. E., Moeller F. G. (2010). Contingency management and levodopa-carbidopa for cocaine treatment: a comparison of three behavioral targets. Exp. Clin. Psychopharmacol. 18, 238–24410.1037/a0019195
    1. Schmitz J. M., Mooney M. E., Moeller F. G., Stotts A. L., Green C., Grabowski J. (2008). Levodopa pharmacotherapy for cocaine dependence: choosing the optimal behavioral therapy platform. Drug Alcohol Depend. 94, 142–15010.1016/j.drugalcdep.2007.11.004
    1. Schmitz J. M., Stotts A. L., Rhoades H. M., Grabowski J. (2001). Naltrexone and relapse prevention treatment for cocaine-dependent patients. Addict. Behav. 26, 167–18010.1016/S0306-4603(00)00098-8
    1. Shearer J. (2008). The principles of agonist pharmacotherapy for psychostimulant dependence. Drug Alcohol Rev. 27, 301–30810.1080/09595230801927372
    1. Shearer J., Wodak A., van Beek I., Mattick R. P., Lewis J. (2003). Pilot randomized double blind placebo-controlled study of dexamphetamine for cocaine dependence. Addiction 98, 1137–114110.1046/j.1360-0443.2003.00447.x
    1. Spitzer R. L., First M. B. (2005). Classification of psychiatric disorders. JAMA 294, 1898–1899; author reply 1899–1900.10.1001/jama.294.15.1898
    1. Stout R. L., Wirtz P. W., Carbonari J. P., Del Boca F. K. (1994). Ensuring balanced distribution of prognostic factors in treatment outcome research. J. Stud. Alcohol Suppl. 12, 70–75

Source: PubMed

Sponsor e collaboratori

Condizioni mediche

Interventi farmacologici

3
Sottoscrivi